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Genetic tests may motivate risk-reducing behaviour more than other
types of tests because they generate higher risk magnitudes and because
their results have high personal relevance. To date, trial designs have not
allowed the disentangling of the effects of these two factors. This
analogue study examines the independent impacts of risk magnitude and
provenance, and of risk display type, on motivation to quit smoking. A
total of 180 smokers were randomly allocated to one of the 18 Crohn’s
disease risk vignettes in a 3 (risk provenance: family history. genetic test
mutation positive. genetic test mutation negative) 3 3 (risk magnitude:
3%, 6%, 50%) 3 2 (display: grouped or dispersed icons) design. The
50% group had significantly higher intentions to quit than the 3% group.
A significant risk provenance 3 magnitude interaction showed that
participants in 50% or 6% groups were equally motivated, regardless of
risk provenance, while participants in the 3% group had higher
intentions associated with a mutation negative result than with a result
based on family history alone. Grouped icon displays were more
motivating than the dispersed icons. Using genetic tests to estimate
risks of common complex conditions may not motivate behaviour
change beyond the impact of the numerical risk estimates derived
from such tests.
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There are high expectations regarding the poten-
tial for DNA-based risk information to motivate
health-related behaviour change more strongly
than other types of risk information (1, 2). Two
factors underpin these expectations. Firstly,
DNA-based risk assessment procedures may
generate a wider range of risk magnitudes than
non-DNA-based risk assessments. For example,
DNA testing can identify the individuals homo-
zygous for a risk-conferring mutation who have
a considerably increased likelihood of develop-
ing the condition in question relative to an aver-
age member of the population. These higher risk
magnitudes generated by DNA-based risk assess-
ments may increase perceived vulnerability to the
health condition and thus motivate risk-reducing
behaviour change better than do lower magnitude
risk estimates generated by non-DNA-based risk
Re-use of this article is permitted in accordance with the Creative
Commons Deed, Attribution 2.5, which does not permit commercial
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assessments. This prediction is consistent with the
evidence that providing disease risk estimates has
a medium-sized effect on risk perceptions, which
in turn have a small effect upon risk-reducing
behaviour (3). Evidence from several theories of
health behaviour (4–6) suggests that risk percep-
tions act in combination with other constructs to
motivate behaviour change. Moreover, perceived
vulnerability to the adverse effects of smoking is
a factor influencing intentions to quit. For exam-
ple, 69% of British smokers who wanted to quit
said that this was due to their wish for better
health (7).
The second reason why DNA-based risk infor-
mation may better motivate behaviour change is
that genetic test results may be viewed as more
personally relevant than risk estimates based on
family history but not incorporating genetic test
results. Theories of attitude change predict that
the greater the perceived personal relevance of
information, the greater its impact (8). Consistent
with this, diagnoses incorporating genetic test re-
sults can be perceived as more accurate than simi-
lar diagnoses made without the use of genetic tests
and so may better motivate behaviour change (9).
Within the context of providing DNA-based
risk estimates, individuals may react differently
to mutation-positive and mutation-negative re-
sults. Genetic risks are viewed as less controlla-
ble than non-genetic risks (10). Given that lay
people’s representations of mutation-negative re-
sults may be that they do not have the gene’ for
the condition, not possessing a mutation may be
interpreted as evidence that a personally relevant
risk is controllable through behaviour change. In
contrast, possessing the mutation may suggest
that the risk is less controllable, so potentially
demotivating behaviour change (11).
Few studies have explored whether DNA-based
risk information does have greater motivational
impact than numerical risk estimates derived
from other sources and, if so, which of the two
distinguishing features of genetic tests account for
this. The small number of clinical studies con-
ducted in this area suggest that the disclosure of
genotypes indicating increased risk of disease is
sometimes (12, 13), but not always (14, 15), asso-
ciated with increased motivation for behaviour
change. The current study aims to assess the
extent to which any motivating impact of DNA-
based risk information is due to the risk magni-
tudes generated by genetic tests or due to the
higher perceived relevance of such information.
It is important to clarify the independent ef-
fects of the risk magnitudes generated by, and
the greater perceived relevance of, genetic tests.
This information will permit clinicians to fore-
cast whether newly identified risk-conferring
gene variants could form the basis of risk-reducing
behaviour change interventions. If motivation is
driven solely by risk magnitude, then gene var-
iants that confer only small increases in the like-
lihood of developing a health problem are
unlikely to motivate behaviour change. In con-
trast, if risk provenance, which affects perceived
relevance of the information, contributes to
motivation, then even risk assessments involving
gene variants that confer small increases in risk
magnitude may increase motivation relative to
non-DNA-based risk assessments, and so have
clinical utility.
Experimental analogue studies allow the effects
of risk magnitude and risk provenance to be
manipulated independently. Participants are
asked to imagine themselves in a situation and
to respond as if they had experienced the events
described. Such studies have good internal valid-
ity and sufficient external validity to merit using
the results to inform the design of clinically
based studies (16–19). Several analogue studies
have compared the motivational effects of
genetic and non-genetic risk information in asso-
ciation with different risk magnitudes. Two stud-
ies (20, 21) found that risk magnitude, but not
risk provenance, influenced intentions for risk-
reducing behaviour. The other study (22) found
evidence supportive of effects of both risk prove-
nance and risk magnitude. However, the lack of
significant differences in intentions between the
low-risk, mutation-negative and the higher risk,
non-DNA group in this study makes its findings
difficult to interpret. Therefore, further evidence
is needed to clarify the independent and interac-
tive effects of risk magnitude and risk prove-
nance on intentions for risk-reducing behaviour.
Moreover, the potentially contrasting effects of
mutation-positive and mutation-negative results
have yet to be examined in a fully multifactorial
risk provenance 3 risk magnitude design.
When trying to maximize the motivational
impact of genetic risk information, a key ques-
tion concerns how to present the risk estimates.
Graphic formats can facilitate risk communica-
tion. Based on a recent review of such formats
(23), it was decided to employ icon arrays to
communicate probabilistic information. Icon ar-
rays have the desirable property that, when icons
are arranged as a group, the ability to estimate
what proportion object A fills of the larger
object B appears to be automatic (24), facilitat-
ing the communication of probabilities. An
alternative arrangement involves randomly dis-
persing affected’ icons throughout the array.
Such dispersed displays may help convey the
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randomness inherent in probabilistic risk infor-
mation, increasing perceived vulnerability to the
adverse outcome and so motivating risk-reducing
behaviour (23, 25). However, dispersed displays
may cause difficulties estimating the proportion
affected (26). The resultant comprehension prob-
lems may reduce the risk information’s motiva-
tional impact. Therefore, the optimal display type
to motivate behaviour change when providing
genetic risk information remains to be determined.
The study focuses on communicating informa-
tion about the risk of Crohn’s disease, a chronic
inflammatory disease of the digestive tract that
can severely affect quality of life. Crohn’s disease
affects about 1 in 1000 people, runs in families
and is more common in smokers. The average
risk for smokers who have a sibling with Crohn’s
disease is 4.6%. The gene CARD15 has been
identified as a susceptibility gene for Crohn’s dis-
ease (27–30). The risk varies depending on the
presence of a particular mutation that increases
the likelihood of developing the disease. For
smokers who have a sibling with Crohn’s disease,
the risk is about 35% when they are homozygous
for CARD15, 8% when they are heterozygous
for CARD15 and 5% when they have no muta-
tion in the gene (31). We are planning a clinical
trial (registered with Current Controlled Trials,
ISRCTN 21633644) examining whether risk as-
sessments for Crohn’s disease including, or not
including, the results of genetic tests influence
motivation to quit. Other trials thus far have
focused on whether communicating genetic risks
of lung cancer motivates quitting (12–14).
The results of the current analogue study will
provide evidence concerning which aspect(s) of
genetic risk information most strongly motivate
behaviour change. This information may help
clinicians to anticipate contexts in which genetic
risk information is more or less likely to succeed
in motivating behaviour change. Thus, the pres-
ent study aims to assess the independent effects
of risk magnitude and risk provenance (genetic
test, mutation positive; genetic test, mutation
negative; based on family history alone) on in-
tentions to stop smoking, and to determine how
best to display this risk information to motivate
behaviour change.
Hypotheses
(1) Genetic risk information generates greater
intentions to stop smoking than risk infor-
mation based only on family history.
(2) Higher magnitudes of risk generate greater
intentions to stop smoking.
(3) Intentions to quit will differ between partic-
ipants who view grouped and dispersed icon
displays.
Materials and methods
Design
Between subjects, 3 (risk magnitude: 3%, 6%,
50%) 3 3 (risk provenance: genetic test, muta-
tion positive; genetic test, mutation negative;
family history only) 3 2(icon array: grouped or
dispersed) experiment using vignettes.
Participants
A total of 75 men and 105 women were recruited
from the general population using a research
agency (n ¼ 140) and from staff and students of
two universities (n ¼ 40) (Table 1). There were
10 participants in each experimental group.
Participants smoked more than one cigarette
per day and had not been diagnosed with
Crohn’s disease. Given the three substantive
hypotheses outlined above, this sample size was
estimated to be sufficient to detect a medium size
main effect of each factor (f ¼ 0.25) with
a ¼ 0.05 and power of 0.8. This sample size is
also sufficient for subsequent pairwise compari-
sons with an adjusted a ¼ 0.01.
Measures
Intentions to stop smoking were assessed using
two items (r ¼ 0.89): Do you intend to stop smok-
ing in the next 4 weeks’, rated from 1:definitely
Table 1. Demographic characteristics and smoking status of
the 180 study participants
Variable Categories n (%)
Gender Male 75 (41.7)
Female 105 (58.3)
Highest educational
qualification
No formal
qualifications
12 (6.7)
GCSEs/O levelsa 39 (21.7)
A levels/further
educationb
43 (23.9)
University degree 75 (41.7)
Other qualifications 11 (6.1)
Time to first cigarette
after waking
Within 5 min 25 (13.9)
6–30 min 75 (41.7)
31–60 min 37 (20.6)
After 60 min 43 (23.9)
Number of cigarettes
per day
1–5 30 (16.7)
6–10 43 (23.9)
11–20 63 (35.0)
21–30 34 (18.9)
31 or more 10 (5.6)
aBritish public examinations traditionally taken at age 16.
bBritish public examinations traditionally taken at age 18.
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not’ to 7: definitely do’, and How likely is it that
you will stop smoking in the next four weeks?’
rated from 1:very unlikely’ to 7:very likely’. Per-
ceived susceptibility to Crohn’s disease was as-
sessed with: If you continue to smoke, how likely
do you think it is that you will develop Crohn’s
disease’, rated from 1: not at all’ – 7:extremely
likely’.
Demographics and smoking behaviour
Participants began the questionnaire by giving
their age, gender and educational qualifications.
Nicotine dependence was assessed using the
Heaviness of Smoking Index (32).
Vignettes
Each vignette asked participants to imagine that
they had a sibling with Crohn’s disease, and pro-
vided information about the condition. Partici-
pants imagined undergoing a risk assessment to
discover their own risk of developing Crohn’s
disease. They were then presented with their
hypothetical risk assessment results and
informed that by stopping smoking their risk
would be halved. It should be noted that the risk
magnitudes provided to participants are different
to those cited in the Introduction. The figures
used in the vignettes were believed, at the time
the study was conducted, to accurately reflect
smokers’ probability of developing Crohn’s dis-
ease in the presence or absence of the CARD15
mutation. However, the risk magnitudes associ-
ated with the interaction between CARD15 and
smoking behaviour have since been amended by
the epidemiologists with whom we are collabo-
rating, subsequent to further data collection
(31). The full vignettes, including the graphical
displays, are shown in Figs 1 and 2.
Statistical analysis
The effects on intentions of risk provenance, risk
magnitude, display type and their interactions
were tested using ANOVA. Simple main effects
analysis was used to determine the form of any
significant interactions.
Procedure
King’s College London Research Ethics Com-
mittee approved the study. Participants were re-
cruited using the e-mail lists of two universities
and a market research agency’s Internet panel.
Panel members complete surveys in return for
Fig. 1. The vignettes used in the study.
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points’, which are exchangeable for various con-
sumer goods at the agency’s partner website.
Participants were provided with 10 points’
(approximate monetary value £1). Internet panel
members were e-mailed a URL that linked to the
vignettes and questionnaire online. University
staff and students were e-mailed the study mate-
rials and questionnaire.
Results
No differences were found between the 18 ran-
domized groups on any of the demographic or
smoking variables and so they were not used as
covariates in the analysis.
Effects on perceived susceptibility
Perceived susceptibility scores according to
experimental group are shown in Table 2, while
Table 3 provides the results of ANOVA.
The main effect of risk magnitude on perceived
susceptibility was not significant. However, the
means were in the predicted direction, with those
in the 3% group reporting lower susceptibility
(mean ¼ 3.85) than the 6% group (mean ¼
3.98), who in turn reported lower susceptibility
than the 50% group (mean ¼ 4.28). There was
also a significant risk magnitude 3 risk prove-
nance interaction. Simple main effects analysis
using a Sidak adjustment for multiple compari-
sons found that perceived susceptibility was
Fig. 2. Details of how the different magnitude risk estimates were communicated.
Wright et al.
310
affected by risk magnitude in the family history
only condition [simple main effect
F(2,162) ¼ 6.13, p ¼ 0.003], but not in either of
the genetic testing conditions. Pairwise compari-
sons revealed that, within the family history con-
dition, the 3% group perceived significantly
lower susceptibility to Crohn’s disease than did
the 6% or 50% groups, while the latter two did
not differ in their perceptions of susceptibility.
Effects on intentions to quit
Mean intentions according to experimental
group are shown in Table 4, while Table 5 shows
the results of the ANOVA.
The main effect of risk provenance was not sig-
nificant, but there was a significant main effect
of risk magnitude on intentions to quit. Sidak-
adjusted pairwise comparisons showed that par-
ticipants who received a 50% risk estimate were
significantly more motivated than participants
who received a 3% risk estimate. The 6% group
fell between these two extremes, not differing
significantly from either.
This effect of risk magnitude on intentions was
modified by a significant risk magnitude 3 risk
provenance interaction. This took the form that,
for participants receiving 50% or 6% risk esti-
mates, risk provenance made no difference to in-
tentions to quit. However, participants in the
3% risk estimate group had stronger intentions
when the risk estimate was based on a mutation
negative result compared with when it was based
on family history alone [simple main effect of
risk provenance in the 3% group: F(2,162) ¼
3.26, p ¼ 0.04]. Finally, the significant main
effect of display type was due to participants
who viewed a grouped display having higher in-
tentions than participants who viewed a dispersed
display.
Discussion
This study examined the effects of risk estimate
provenance, risk magnitude and display type on
motivation to quit smoking. The greater the
magnitude of the risk estimates the stronger were
the participants’ intentions to adopt risk-reduc-
ing behaviour. Mean perceived susceptibility to
Crohn’s disease was higher in the higher risk
magnitude groups, suggesting that risk magni-
tude influenced susceptibility and so intentions.
Table 2. Perceived susceptibility to Crohn’s disease, accord-
ing to risk provenance, risk magnitude and display
Risk provenance
Risk
magnitude
(%)
Display type
Dispersed Grouped
Mean SD Mean SD
Mutation positive 3 3.80 1.23 4.60 1.17
6 4.50 1.51 3.50 1.58
50 3.80 1.14 4.10 1.66
Mutation negative 3 3.60 1.43 4.50 1.08
6 3.60 1.17 3.50 0.97
50 4.20 1.55 4.10 1.10
Family history only 3 3.70 1.64 2.90 1.20
6 4.20 1.69 4.60 1.58
50 4.70 1.42 4.80 1.14
Table 3. Results of ANOVA examining effects of risk magni-
tude, risk provenance and display type on perceived
susceptibility to Crohn’s disease
Effect d.f. F p
Partial
Z2
Risk magnitude 2 1.583 0.209 0.019
Risk provenance 2 0.440 0.645 0.005
Display type 1 0.074 0.785 0.000
Risk magnitude 3 risk provenance 4 2.922 0.023 0.067
Risk magnitude 3 display type 2 0.583 0.559 0.007
Risk provenance 3 display type 2 0.226 0.798 0.003
Risk magnitude 3 risk
provenance 3 display type
4 1.833 0.125 0.043
Table 4. Intentions to quit smoking, according to risk
provenance, risk magnitude and display
Risk provenance
Risk
magnitude
(%)
Display type
Dispersed Grouped
Mean SD Mean SD
Mutation positive 3 2.50 1.27 3.20 1.93
6 2.85 1.55 3.00 1.56
50 3.75 2.29 4.30 1.55
Mutation negative 3 2.75 1.34 4.25 1.16
6 3.10 2.07 2.25 1.34
50 3.30 1.99 3.90 1.68
Family history only 3 2.15 1.49 2.15 1.87
6 2.80 1.44 4.60 1.70
50 2.90 1.56 3.85 1.84
Table 5. Results of ANOVA examining effects of risk magni-
tude, risk provenance and display type on intentions to quit
smoking
Effect d.f. F p
Partial
Z22
Risk magnitude 2 3.890 0.022 0.046
Risk provenance 2 0.252 0.778 0.003
Display type 1 5.798 0.017 0.035
Risk magnitude 3 risk provenance 4 2.918 0.023 0.067
Risk magnitude 3 display type 2 0.221 0.802 0.003
Risk provenance 3 display type 2 0.407 0.666 0.005
Risk magnitude 3 risk
provenance 3 display type
4 1.946 0.105 0.046
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However, this interpretation must be considered
tentative, as although the pattern of mean sus-
ceptibility scores was as predicted, the size of the
differences was not sufficient to be statistically
significant.
Only when the magnitude of the risk estimate
was lowest (3%) did risk provenance make a dif-
ference to intentions. Participants in the 3%
group for whom the estimate was based on
a mutation-negative result were more motivated
than participants receiving an estimate of identi-
cal magnitude based on family history alone. In-
tentions for those in the mutation-positive group
were intermediate between these two extremes.
One possible explanation for this finding is that
genetic test results were perceived as more rele-
vant and so motivating than were risk estimates
based on family history alone. However, muta-
tion-positive results may also have been inter-
preted as suggesting that the likelihood of
developing Crohn’s disease was less controllable,
resulting in this group having lower intentions to
quit than the mutation-negative group. Given
this interaction was not predicted, replication is
required to ensure it is a robust finding.
The significant main effect of risk magnitude
on intentions echoes the findings of previous
vignette studies (20–22). However, the finding of
a significant risk magnitude 3 provenance inter-
action differs from that of the only other
vignette study to test this interaction (20). This
discrepancy could result from the differing val-
ues of the risk magnitudes used in two studies,
or from the current study presenting both rela-
tive and absolute risk estimates, whereas the
earlier study communicated only relative risks.
Presenting the probabilistic information using
grouped icons led to greater intentions to quit
than when the same information was presented
using dispersed icon displays. This finding ac-
cords with the other work, which suggests that
grouped displays make it easier for participants
to appreciate the relative magnitudes of risks
and so may more strongly motivate risk-reduc-
ing behaviour (23), and with the suggestion that
dispersed displays may cause comprehension dif-
ficulties and so reduce motivation. It appears
that presenting risk estimates associated with
genetic risk information using grouped icon dis-
plays may maximize any motivational effects.
Strengths, limitations and suggestions for
further research
This study’s major strength is that it allowed the
motivational effects of risk provenance to be dis-
entangled from those of risk magnitude, and that
it includes both mutation-positive and mutation-
negative genetic testing conditions. The study
also benefits from using a sample reasonably
representative of British smokers (33). Experi-
mental vignettes cannot completely reflect the
nature of complex encounters between health
professionals communicating risk information
and their patients. However, analogue methods
permitted the separation of two key factors that
would not be possible to achieve in a clinical
context. One further limitation is that there was
a small error in the second page of information
seen by the family-history-based risk estimate
groups. On the first page of information,
although genetic testing was not mentioned, on
the second page participants were asked to
Imagine 1000 people, with the same genetic test
result, and who smoke, and who have a brother
or sister with the disease’. This mention of
a genetic test result in what was intended to be
a family-history-only condition may have
obscured the motivational impact of risk prove-
nance. However, the effect size for the main
effect of risk provenance was less than one-tenth
that for display type or magnitude. Therefore, it
seems unlikely that risk provenance would have
significantly influenced intentions even if this
error had not been made.
Clinicians and researchers investigating whether
genetic risk information can motivate risk-
reducing behaviour change should include further
manipulation checks on participants’ beliefs to
facilitate understanding of the processes causing
any observed differences in motivation for, and
practice of, risk-reducing behaviours. Such mea-
sures should include participants’ perceptions of
the precision and personal relevance of the risk
estimate, which we predict will be greater in
conditions where risk estimates include a genetic
test result than in conditions where risk estimates
are not based on a genetic test result. Future
research would also benefit from deeper explo-
ration of participants’ perceptions of the risk
information, including whether high-magnitude
risk estimates are viewed as credible and how
well participants comprehend the information.
Conclusions
Higher risk magnitudes better motivate behav-
iour change, regardless of whether they are
derived from genetic tests or not. Risks pre-
sented using grouped, as opposed to dispersed,
displays are also more motivating. Although the
motivational impact of genetic testing may be
Wright et al.
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most evident following the presentation of risks
of low magnitude, the results of this study are
compatible with the hypothesis that using
genetic tests to estimate risks of common com-
plex conditions will not motivate behaviour
change beyond the motivating impact of the risk
magnitudes derived from such tests.
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